Ocuphire Pharma (Nasdaq: OCUP) has announced the acquisition of Opus Genetics, a clinical-stage gene therapy company focused ...

Canaccord lowered the firm’s price target on Ocuphire Pharma (OCUP) to $10 from $18 and keeps a Buy rating on the shares. The firm noted ...

Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

On Wednesday, Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced the all-stock acquisition of Opus Genetics, Inc., a ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

In 2022, Opus Genetics signed an agreement with National Resilience for developing and manufacturing AAV vector-based gene ...

In the transaction, Ocuphire will issue 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing stokholders of Opus Genetics. Ocuphire insiders ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. Published first on TheFly – the ultimate source for ...

The company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for ...

"We are honored to welcome Alison to the Artiva Board of Directors. Her decades of executive experience in manufacturing and ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...